{"type":"trials","record":{"id":41855,"source_id":"clinicaltrials-gov","external_id":"NCT06839339","title":"Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD","brief_summary":"This Phase II study is designed to evaluate the efficacy and safety of AL-001 ophthalmic injection in patients with wet age-related macular degeneration. Eligible patients, who meet the inclusion/exclusion criteria and have shown an anatomic response to an anti-VEGF (Vascular Endothelial Growth Factor) injection, will be randomized in Cohorts 1 and 2 to receive AL-001 administered via suprachoroidal space injection, Cohort 3 to receive Aflibercept.","overall_status":"Not Yet Recruiting","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Beijing Anlong Biopharmaceutical Co., Ltd.","enrollment":40,"countries":["China"],"start_date":"2025-02-18","completion_date":"2027-01-30","last_update_date":"2025-02-21","source_url":"https://clinicaltrials.gov/study/NCT06839339","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years to 85 Years","comparator":"Aflibercept","organization":"Beijing Anlong Biopharmaceutical Co., Ltd.","interventions":["AL-001","Aflibercept"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Evaluate the effect of AL-001 on BCVA — Week 24","Safety — Week 56","Evaluate the effect of AL-001 on central retinal thickness (CRT) — Week 56"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Wet Age-related Macular Degeneration (wAMD)","AL-001","Aflibercept"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06839339","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-02-18 to 2027-01-30","comparator":"Aflibercept","confidence":"structured-source","population":"ALL · 50 Years to 85 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.881Z","intervention":["AL-001","Aflibercept"],"participants":40,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Evaluate the effect of AL-001 on BCVA — Week 24","Safety — Week 56","Evaluate the effect of AL-001 on central retinal thickness (CRT) — Week 56"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41855","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}